New GE Healthcare will host a webinar on the uses of contrast media in echocardiology and an update on their contrast agent: Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP). Please click here for more information and to register.
New GE Healthcare receives FDA approval to manufacture Optison™ in-house
GE Healthcare receives FDA approval to manufacture OptisonTM in-house, ensuring more consistent supply to the market. Read the full press release here.
New New TTE with contrast yielded lower mortality than non-contrast TTE in critically ill patients
More coverage of large new study showing safety and lower mortality rates of Contrast Enhanced Ultrasound (CEUS) in critically ill patients. Read more here.